Suzhou Huiliao Bio: Moving Forward with Honors, Leading the New Journey of Veterinary Nucleic Acid Drugs.

Recently, a significant event focusing on the development of veterinary nucleic acid drugs—the Founding Conference of the Nucleic Acid Drugs Branch of the China Veterinary Drug Association and the Seminar on Key Technologies of Nucleic Acid Drugs—was grandly held in Tianjin.

This conference brought together industry elites, aiming to consolidate efforts and precisely focus on the research, development, and industrialization of veterinary mRNA vaccines and other nucleic acid drugs, laying a solid foundation for innovation in the veterinary drug field. Suzhou Huiliao Biotechnology Co., Ltd., as an industry pioneer, participated deeply in this event.

Thanks to its long-term dedication, professional expertise, and innovative ideas in the field of nucleic acid drugs, Huiliao Biotechnology successfully stood out among its peers and, after a rigorous selection process, was honored to be appointed as the Vice President Unit of the Nucleic Acid Drugs Branch, marking the beginning of a new chapter.

This honor not only highly recognizes the company's past achievements but also entrusts it with new responsibilities and missions. Standing at this new starting point, Huiliao Biotechnology will adhere to its spirit of innovation, continue to delve into its professional field, and persistently explore the potential of nucleic acid drug development.

At the same time, Dr. Zhao Lixiang, the company's co-founder and CTO, was successfully appointed as a member of the first Think Tank Expert Group of the Nucleic Acid Drugs Branch of the China Veterinary Drug Association, thanks to his profound academic expertise, forward-looking vision, and extensive practical experience. This achievement places him among the industry's leading intellectual figures.

Zhao Lixiang

Ph.D. Supervisor, Professor at the Department of Immunology, Suzhou University School of Medicine; Director of the mRNA Drug Collaborative Innovation Center; Co-founder of Suzhou Huiliao Biotechnology Co., Ltd.

His primary research focuses on mRNA vaccines and tumor immunotherapy. In recent years, he has published dozens of papers in renowned journals such as Leukemia, Cancer Research, Cancer Immunology Research, mBio, JVI, and Journal of Immunology. He holds multiple authorized patents for vaccine inventions and has led several national and provincial-level research projects.

Looking ahead, Suzhou Huiliao will seize this opportunity to continue its in-depth exploration of the nucleic acid drug field. The company will fully support the association's initiatives, actively organize and participate in various activities, and build platforms for communication and collaboration. By promoting resource sharing and complementary advantages, Huiliao aims to pioneer new development pathways. Together with industry peers, the company will strive to create a brilliant future for the industry and lead veterinary nucleic acid drugs toward new heights of success.

#About Suzhou Huiliao #

Suzhou Huiliao Biotechnology is a high-tech enterprise engaged in the comprehensive provision of nucleic acid drug industrialization. The company's business spans the research and production of mRNA drugs, clinical trial design, data analysis, and other areas, with a focus on the development of mRNA technology-based infectious disease vaccines, cancer vaccines, cell therapies, protein replacements, and more.